Originally published In Press as doi:10.1074/jbc.M200680200 on March 5, 2002
J. Biol. Chem., Vol. 277, Issue 19, 17367-17373, May 10, 2002
Mutant Neuroserpin (S49P) That Causes Familial Encephalopathy
with Neuroserpin Inclusion Bodies Is a Poor Proteinase Inhibitor and
Readily Forms Polymers in Vitro*
Didier
Belorgey
§,
Damian C.
Crowther¶
,
Ravi
Mahadeva
, and
David A.
Lomas
From the
Respiratory Medicine Unit and
¶ Neurology Unit, Department of Medicine, University of
Cambridge, Cambridge Institute for Medical Research, Wellcome
Trust/Medical Research Council Building, Hills Road, Cambridge CB2
2XY, United Kingdom
Received for publication, January 22, 2002
 |
ABSTRACT |
Familial encephalopathy with neuroserpin
inclusion bodies (FENIB) is an autosomal dominant dementia that is
characterized by intraneuronal inclusions of mutant neuroserpin. We
report here the expression, purification, and characterization of
wild-type neuroserpin and neuroserpin containing the S49P mutation that causes FENIB. Wild-type neuroserpin formed SDS-stable complexes with
tPA with an association rate constant and Ki of 1.2 × 104
M
1 s
1 and 5.8 nM,
respectively. In contrast, S49P neuroserpin formed unstable complexes
with an association rate constant and Ki of
0.3 × 104
M
1 s
1 and 533.3 nM, respectively. An assessment by circular dichroism showed that S49P neuroserpin had a lower melting temperature than wild-type protein (49.9 and 56.6 °C, respectively) and more readily formed loop-sheet polymers under physiological conditions. Neither the
wild-type nor S49P neuroserpin accepted the P7-P2
1-anti-trypsin or P14-P3 antithrombin-reactive loop
peptides that have been shown to block polymer formation in other
members of the serpin superfamily. Taken together, these data
demonstrate that S49P neuroserpin is a poor proteinase inhibitor and
readily forms loop-sheet polymers. These findings provide strong
support for the role of neuroserpin polymerization in the formation of
the intraneuronal inclusions that are characteristic of
FENIB.
 |
INTRODUCTION |
An increasing number of neurodegenerative disorders are recognized
to result from the aggregation of proteins within the tissues of the
central nervous system (1-3). In conditions such as Alzheimer's disease, Huntington's disease, and the prion encephalopathies, the
protein deposition is associated with a conformational transition within the protein and aberrant
-strand linkage. Indeed, these and
other disorders have now been grouped together as a new class of
conditions, the conformational diseases (4-6). Our understanding of
the mechanisms underlying these neurodegenerative diseases has been
enhanced by the recent description of a new dementia, familial
encephalopathy with neuroserpin inclusion bodies
(FENIB)1 (7, 8). FENIB is
characterized by the accumulation of neuroserpin as periodic
acid-Schiff-positive diastase-resistant inclusions or Collins' bodies
within the deep layers of the cerebral cortex. The original FENIB
kindred presented with presenile dementia and cognitive deficits that
are unlike those of Alzheimer's or Huntington's disease (7-10).
A genetic analysis of two families with FENIB revealed point mutations
in helix B of the neuron-specific protein, neuroserpin (8). Neuroserpin
is an axonally secreted member of the serine proteinase inhibitor or
serpin superfamily (11-15). Members of this family share a similar
molecular architecture based on a dominant
-sheet A and a mobile
inhibitory reactive center loop (16). The reactive center loop presents
a peptide substrate to the target proteinase. Following docking, the
reactive loop is cleaved, and the proteinase is inhibited by
translocation over 70 Å to the lower pole of the inhibitor (16, 17).
The most probable target for neuroserpin is tissue plasminogen
activator (tPA) (13, 18, 19), and it has been suggested that
neuroserpin-tPA interactions play an important role in regulating
neuronal and synaptic plasticity and memory (20-27).
The "mousetrap" mechanism is central to the inhibitory function of
the serpins but renders them susceptible to mutations that facilitate
aberrant conformational change (16). This process is best characterized
for the serpin
1-antitrypsin (28, 29). Point mutations
of
1-antitrypsin perturb the relationship between the
reactive center loop and
-sheet A. This allows the sequential incorporation of the reactive loop of one molecule into
-sheet A of
another to form chains of polymers that are retained within hepatocytes
(30-32). These polymers tangle to form periodic acid-Schiff-positive, diastase-resistant inclusions that are associated with neonatal hepatitis, juvenile cirrhosis, and hepatocellular carcinoma (33). It
was very striking that the mutations that underlie FENIB were in the
same shutter domain of the serpin molecule as those that caused
polymerization of
1-antitrypsin with accompanying liver disease (8, 34). Indeed, the examination of protein from the brains of
affected individuals demonstrated that the inclusions were composed
solely of mutant neuroserpin and that this had formed chains of
loop-sheet polymers identical to those of mutant
1-antitrypsin, which accumulate within the liver (8, 9,
35).
Thus, it seems likely that the accumulation of neuroserpin polymers
within the brain causes neuronal loss and hence dementia. However,
there is evidence that neuroserpin is neuroprotective (36), and that a
shift in the balance between plasminogen and plasmin balance can also
cause neuronal cell death (37). Moreover, it is impossible to predict
whether the shutter domain mutants retain inhibitory activity. We
report here the expression, purification, and characterization of
wild-type neuroserpin and neuroserpin containing the S49P mutation that
underlies FENIB. We show that S49P neuroserpin is not effective as a
proteinase inhibitor and rapidly forms polymers under physiological conditions.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Restriction enzymes and T4 DNA ligase
were purchased from New England Biolabs (Hitchin, UK), and
oligonucleotides were synthesized by Invitrogen (Paisley, UK). The
expression vector pQE31 was from Qiagen (Crawley, UK). Ampicillin,
kanamycin, and isopropyl-
-D-thiogalactopyranoside were
from Melford Laboratories Ltd. (Ipswich, UK). HiTrap chelating HP and
HiTrap Q-Sepharose were from Amersham Biosciences. The tPA substrate
S-2288
(H-D-Ile-Pro-Arg-para-nitroanilide)
was from Chromogenix (Quadratech, Epsom, UK).
1,5-Dansyl-Glu-Gly-Arg-chloromethylketone and tPA were from Calbiochem.
Unless otherwise stated, all experiments were carried out in a solution
referred to as the buffer (50 mM Tris-HCl, 50 mM KCl, pH 7.4). Synthetic peptides corresponding to the
P7-P22 sequence of the
reactive center loop of
1-antitrypsin (FLEAIG) and
P14-P3 sequence of antithrombin (SEAAASTAVVIA) were synthesized and
purified by Genosys Biotechnologies Inc. (Cambridge, UK) and MWB
(Cambridge, UK), respectively. They were dissolved in 50 mM Tris-HCl, pH 7.4, and water, respectively.
Construction and Mutagenesis of Expression Plasmids--
The
pUAST vector containing the cDNA for human neuroserpin was kindly
provided by Dr. Clare Green (Department of Genetics, University of
Cambridge, UK). Neuroserpin was amplified by the polymerase chain
reaction and inserted into the expression vector pQE31 by the
restriction sites BamHI and KpnI. The S49P
mutation was introduced by a two-step polymerase chain reaction. The
sequence of the wild-type and mutant neuroserpin was confirmed by DNA
sequencing of the entire neuroserpin gene. Recombinant proteins were
expressed with a six-histidine tag at the N terminus.
Expression and Purification of Recombinant
Proteins--
Escherichia coli were transformed with the
plasmid containing wild-type and mutant neuroserpin, and the proteins
expressed as described previously for
1-antitrypsin
(38). The cells were harvested by centrifugation, resuspended in buffer
A (50 mM Tris-HCl, 100 mM NaCl, 10 mM EDTA, pH 7.8), and disrupted by sonication. The cell
pellet was washed three times with buffer A containing 0.05% v/v
Triton X-100 and once again with buffer A alone prior to solubilization
in 10 mM Tris-HCl, 100 mM
NaH2PO4, 6 M guanidinium-HCl, pH
8.0. The protein was then refolded drop by drop overnight at 4 °C in
20 mM Na2HPO4, 100 mM
NaCl, pH 7.8. This solution was loaded onto a HiTrap chelating column
precharged with 0.1 M NiSO4. The bound protein
was eluted as a single peak with an imidazole gradient (0-0.3
M). The fractions were collected, dialyzed against buffer B
(20 mM Tris-HCl, 20 mM NaCl, pH 7.4), and
loaded onto a HiTrap Q-Sepharose column. The bound protein was eluted
with a NaCl gradient (0-1 M), dialyzed against 50 mM Tris-HCl, 50 mM KCl, pH 7.4, concentrated,
and then stored at
70 °C. Purified neuroserpin migrated as a
single band on SDS-PAGE and >90% was in a monomeric form when
assessed by nondenaturing and transverse urea gradient PAGE (39).
Complex Formation Assays--
Wild-type neuroserpin (NS) and
mutant neuroserpin (NS(S49P)) were incubated with varying amounts of
tPA at 25 °C. Samples were taken at different time intervals, and
the reaction was stopped by the addition of 1 mM
1,5-dansyl-Glu-Gly-Arg-chloromethylketone (final concentration) to
inhibit any free tPA (40). The samples were then mixed with SDS-PAGE
loading buffer, snap-frozen in liquid nitrogen, and stored until the
completion of the experiment. They were then thawed and boiled for 3 min. Proteins were resolved on a 10% w/v SDS gel and visualized by
staining with Coomassie Blue. The density of the complex band was
determined by densitometry scanning with the data being analyzed by a
semilog plot against time using the software Quantity One
(Bio-Rad).
Determination of the Reaction Parameters Describing tPA
Inhibition--
Inhibition rate constants (ka
and kd) for the inhibition of tPA by NS or
NS(S49P) were determined under pseudo-first order conditions,
i.e. [I]
10 [E]0, using the
progress-curve method (41, 42). Rate constants of inhibition were
measured at 25 °C in inhibition buffer (50 mM Hepes, 150 mM NaCl, 0.01% w/v dodecyl-maltoside, pH 7.4) by adding
tPA (20 nM) to a mixture of NS (from 200 to 1000 nM) or NS(S49P) (2000 nM) and the substrate
S-2288 (1 mM) and recording the release of product as a
function of time. The progress curves were analyzed according to
Equation 1 (42, 43):
|
(Eq. 1)
|
where vz is the initial velocity,
vs is the steady-state velocity at completion of
the reaction, and kobs is the pseudo-first order
rate constant for the approach to the steady state. The values for the
different variables were obtained by fitting the progress curve to
Equation 1 using nonlinear regression analysis and were used to
calculate ka according to Equation 2 assuming that the inhibition conforms to a simple bimolecular reaction (42,
43)
|
(Eq. 2)
|
where Km of S-2288 at 25 °C in the
inhibition buffer was 1.2 mM (±0.1) as measured
independently. The final kinetic parameters are the mean ± S.D.
of at least three experiments.
Circular Dichroism--
Circular dichroism (CD) experiments were
performed using a JASCO J-810 spectropolarimeter in buffer (50 mM Tris-HCl, 50 mM KCl, pH 7.4). Changes in the
secondary structure of NS or NS(S49P) with time and temperature were
measured by monitoring the CD signal at 216 nm for 24 h with
protein concentrations between 0.5 and 1 mg/ml. The data were fitted to
single or double exponential functions. Thermal unfolding experiments
were performed by monitoring the CD signal at 216 or 222 nm between 25 and 95 °C using a heating rate of 1 °C/min at a concentration of
0.5 or 1 mg/ml. Melting points (Tm) were calculated
using an expression for a two-state transition as described previously
(44, 45). The results are the average of three experiments.
Polymerization of NS and NS(S49P)--
Polymerization of NS and
NS(S49P) was assessed by nondenaturing PAGE in buffer (50 mM Tris-HCl, 50 mM KCl, pH 7.4). NS or NS(S49P)
were incubated at a concentration ranging from 0.25 to 1 mg/ml at a
temperature from 4 to 45 °C. Aliquots were taken overtime, and 2 µg of protein were loaded on a 7.5% w/v nondenaturing gel. The
proteins were visualized by staining with Coomassie Blue or by silver staining.
Peptide Insertion--
NS or NS(S49P) were incubated for 24 h at 0.5 mg/ml in the presence of a 100-fold molar excess of a 6-mer
peptide corresponding to the P7-P2 region of the reactive center loop
of
1-antitrypsin or a 12-mer peptide corresponding to
the P14-P3 region of the reactive center loop of antithrombin. As the
polymerization of NS or NS(S49P) was fast compared with
1-antitrypsin and antithrombin, the experiments were
conducted at both 37 and 15 °C. The results were analyzed by loading
the sample onto a 7.5% w/v nondenaturing gel with or without 8 M urea (46). The presence of polymers was visualized by
silver staining.
 |
RESULTS |
Inhibitory Activity of NS and NS(S49P)--
The progress curve for
wild-type neuroserpin did not reach a plateau, but the absorbance
steadily increased with time. This indicates that the mechanism of
inhibition is reversible, or that the enzyme adsorbs to the walls of
the spectrophotometer cuvette and thus escapes inhibition (47).
However, the value of vs was reproducible for a
fixed inhibitor concentration, and the profile of
vs versus [I] was hyperbolic and
fitted well to a classical, fully competitive inhibition mechanism. The
progressive increase in absorbance can therefore be attributed to the
dissociation of the complex. This allowed calculation of the
dissociation and association rate constants from Equation 2. The
apparent pseudo-first order rate constant kobs
increased linearly with the NS concentration up to 1 µM
(Fig. 1A). Within this
concentration range, the mechanism of inhibition of tPA by NS is
consistent with a one-step reaction (41). A ka
value of 1.2 × 104
M
1 s
1 and a
kd value of 7 × 10
5
s
1 were calculated by regression analysis of the data
using Equation 1 (Table I).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Inhibition of tPA by NS or NS(S49P) at pH 7.4 and 25 °C. A, the effect of NS on
kobs, the pseudo-first order constant of tPA
inhibition in the presence of 20 nM tPA. The theoretical
curve has been calculated using Equation 2 and the best estimates of
ka and kd.
B, a typical progress curve for the inhibition of tPA
at 20 nM by NS(S49P) at 2 µM.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Kinetic constants for the inhibition of tPA by NS and NS(S49P) at
25 °C and pH 7.4
The errors on the kinetic parameters ka and
kd are <10 and <20% for Ki.
The results are the mean ± S.D. of three experiments.
|
|
The incubation of mutant NS(S49P) with tPA also resulted in a progress
curve that did not reach a plateau (Fig. 1B). The progress curve clearly shows a pre-steady-state release of product followed by a
steady state, but in addition there is an increase in the rate of
substrate hydrolysis. The first derivative of the data indeed shows an
increase in the rate of hydrolysis after 30 min (data not shown). We
were not able to follow the inhibition of tPA by NS(S49P) at the lowest
concentration used for its inhibition by NS, and therefore, the rate
constants kd and ka were
only determined at a NS(S49P) concentration of 2 µM.
Because of the increase in the rate of hydrolysis of the substrate
after 30 min, the first 30 min of the progress curve were used to
determined the kinetic constants. We calculated values of 0.3 × 104 M
1 s
1 and
1.6 × 10
3 s
1 for
ka and kd, respectively
(Table I).
Stability of Complexes--
The stability of the neuroserpin-tPA
complex was also assessed by SDS-PAGE. NS forms an SDS-stable complex
(Fig. 2A) as has been reported
previously (18). After formation of the complex and inhibition of free
tPA by 1,5-dansyl-Glu-Gly-Arg-chloromethylketone, there is the
appearance of reactive loop-cleaved NS over time. This demonstrates
dissociation of the covalent complex. The small amount of cleaved NS at
the earliest time point in Fig. 2A, lane 2, shows
that the substrate pathway has only a minor effect on the turnover of
wild-type NS. Densitometric analysis of the SDS-PAGE gel allowed the
calculation of a kd for the NS·tPA complex of 1 × 10
4 s
1, a value comparable with
that determined by direct measurement (Fig. 2B).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
10% w/v SDS-PAGE to assess the complex
formed between tPA and NS or NS(S49P). A,
dissociation of the NS·tPA complex at a 2:1 molar ratio at 25 °C.
Lane 1, NS; lanes 2-14 correspond to 1-, 5-, 15-, 30-, 60-, 90-, 120-, 150-, 180-, 240-, 300-, 360-, and 480-min
time points; lane 15, tPA. Lanes 1-14
contain 2 µg of neuroserpin, and lanes 2-15 contain 2 µg of tPA. The native reactive center loop cleaved and complex
(cpx) bands are shown. B, the fractional
loss (ln(fxn)) of density of the complex bands on
the SDS gel was plotted against time to calculate a
kd of 1 × 10 4 s 1. C, the formation
of the NS(S49P)·tPA complex over a range of molar ratios. Lane
1, molecular mass markers; lanes 2-8 correspond to
NS(S49P):tPA ratios of 1, 2, 3, 4, 6, 8, and 12, respectively;
lane 9, NS(S49P); lane 10, tPA. Lane
9 contains 2 µg of NS, and lane 10 contains 2 µg of tPA. NS(S49P) and tPA were incubated for 3 min at
25 °C prior to the addition of
1,5-dansyl-Glu-Gly-Arg-chloromethylketone and then incubated for an
additional minute. Loading buffer was then added, and the samples were
heated and assessed by 10% w/v SDS-PAGE.
|
|
The complex formed between NS(S49P) and tPA more readily favors the
substrate pathway. The analysis of the gel is complicated by the fact
that the Ki describing the interaction between NS(S49P) and tPA is high (~0.5 µM) as determined
kinetically. Even at a 12-fold molar excess of inhibitor, the
dissociation process is not negligible (t1/2
dissociation = ~7 min). Moreover, the complex that forms at a
high ratio of NS(S49P) to tPA rapidly dissociates to give the reactive
loop-cleaved protein, even if the remaining tPA activity is
inhibited by 1,5-dansyl-Glu-Gly-Arg-chloromethylketone (Fig.
2C).
Circular Dichroism--
The melting points for NS and NS(S49P)
were measured by monitoring the change in CD signal at 216 and 222 nm
(data not shown) while increasing the temperature at 1 °C/min. Fig.
3, A and B, show
typical melting curves for NS and NS(S49P) at 216 nm where the change
in signal was the most pronounced. In both cases, there was a decrease
in signal, but the amplitude was very different. The change in NS was
large enough to readily calculate a Tm of 56.6 (±0.3) °C. The change in signal was far less at the same concentration for NS(S49P) with a calculated Tm of
49.9 (±1.2) °C. This difference in amplitude was not the result of a gross conformational transition within NS(S49P), because it had a
typical serpin-unfolding transition on transverse urea gradient PAGE
(Fig. 3C). These gels also showed that NS was more stable than NS(S49P) with an unfolding transition at ~6 M urea
compared with 1 M urea for the mutant protein. NS and
NS(S49P) were also incubated at 0.25 mg/ml between 4 and 90 °C for
15 min and then assessed by nondenaturing PAGE. Polymers appeared
between 50 and 60 °C for NS and between 40 and 50 °C for
NS(S49P), in good agreement with the Tm calculated
from the CD spectra (data not shown).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
CD signal at 216 nm for NS at 1 mg/ml
(A) or NS(S49P) at 1 mg/ml (B) at pH 7.4 while
increasing the sample temperature at 1 °C/min. C, 7.5%
w/v transverse urea gradient PAGE of NS (left) and NS(S49P)
(right). The left and right of the gel
represent 0 and 8 M urea, respectively.
|
|
Polymerization of Neuroserpin--
Differences were observed in
the far-UV CD spectra between NS and NS(S49P). Fig.
4A shows that in their native
form, the two inhibitors adopt a different configuration. The spectra
for NS is very similar to the one observed for native
1-antitrypsin (48). In comparison, the CD profile for
NS(S49P) was significantly more negative with an important increase in
magnitude of the signal at 216 nm and a less significant decrease at
222 nm. Spectra were also taken after polymerization at 45 °C for
24 h. In both cases, the spectra were very similar to the one
obtained for native NS(S49P) and were consistent with the formation of
loop-sheet polymers as observed for
1-antitrypsin (48).
This decrease in the magnitude of the signal at 216 nm was followed
over a period of 24 h at different temperatures and used to
calculate rates of polymerization (Table
II). As noted previously, the amplitude
of the change was larger for NS than for NS(S49P) (Fig. 4, B
and C). The rate of polymerization of NS was independent of
protein concentration over the range of 0.25-1 mg/ml but showed a
progressive increase at higher temperatures with a maximum value of
1.32 × 10
4 s
1 at 45 °C. In
comparison, the rate of polymerization at different temperatures was
constant for NS(S49P) with a value that was almost 13-fold higher than
that obtained for NS at 37 °C.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Far-UV CD spectra of native and polymeric NS
and NS(S49P). A, the far-UV CD spectra of native NS
(crossed line), NS polymers (solid line), native
NS(S49P) (dashed line), and NS(S49P) polymers (dotted
line). Polymers were formed by incubating NS or NS(S49P) at 0.5 mg/ml at 45 °C for 24 h and were confirmed by nondenaturing
PAGE. The results are the mean ± S.D. of three experiments.
B, the change in the CD signal at 216 nm over time for
NS at 0.7 mg/ml at 37 °C (upper curve), 41 °C
(middle curve), and 45 °C (lower curve).
C, shows the change in the CD signal at 216 nm over time for
NS(S49P) at 37 °C and 0.5 mg/ml.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Rate of polymerization of neuroserpin at 1 mg/ml as measured by the
change in CD spectra at 216 nm
The results are the average of three experiments and the errors are
<10%.
|
|
The effect of temperature on the polymerization of NS and NS(S49P) was
also assessed by nondenaturing PAGE (Fig.
5A). Both NS and NS(S49P)
readily formed polymers at 37 °C and 0.25 mg/ml. However, polymers
were already visible for NS(S49P) after 2 h of incubation, whereas
the ladder of polymers was only clearly visible for NS after 4 h
of incubation. After 24 h, both NS and NS(S49P) formed high order
aggregates that were stacked at the top of the gel. Similar results
were obtained over a concentration range of 0.25 to 1 mg/ml. Polymer
formation was also assessed over a range of temperatures. Fig.
5B demonstrates that NS and NS(S49P) formed polymers at
temperatures as low as 4 °C. However, whereas NS formed dimers,
NS(S49P) formed higher order polymers.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 5.
Polymerization of NS and NS(S49P).
A, NS or NS(S49P) were incubated at 37 °C, and 0.25 mg/ml
and aliquots taken over time were analyzed by 7.5% w/v nondenaturing
PAGE. Lanes 1-5 correspond to a 0-, 2-, 4-, 6-, and 8-h
incubation time for NS (lane 1) or NS(S49P) (lane
2). B, the formation of NS or NS(S49P) polymers
when monomeric protein was incubated for 24 h at 0.5 mg/ml over a
range of temperatures. Lanes 1-5 correspond to 0, 4, 10, 16, and 22 °C incubation temperatures for NS (lane 1) or
NS(S49P) (lane 2).
|
|
Peptide Insertion--
Neither the 6-mer P7-P2
1-antitrypsin peptide nor the 12-mer P14-P3 antithrombin
peptide prevented the polymerization of NS or NS(S49P) at 37 °C. The
experiments were then repeated at 15 °C in an attempt to reduce the
rate of polymerization and hence favor the binary complex between NS
and NS(S49P) and the peptide. However, even at 15 °C there was no
binary complex between the peptides and NS or NS(S49P) (Fig.
6). We were unable to assess the effects
of a 12-mer peptide corresponding to the P14-P3 region of the reactive
center loop of neuroserpin because of its poor solubility.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 6.
Peptide insertion experiments. 6-mer
1-antitrypsin and 12-mer antithrombin peptides were
incubated in 100-fold molar excess with M or Z
1-antitrypsin, NS, or NS(S49P) at 15 °C, and the
samples were loaded on a 7.5% w/v nondenaturing gel with 8 M urea. Lane 1, Z 1-antitrypsin;
lane 2, Z 1-antitrypsin 24 h; lane
3, Z 1-antitrypsin 24 h + P7-P2
1-antitrypsin 6-mer peptide; lane 4, M
1-antitrypsin; lane 5, M
1-antitrypsin 24 h; lane 6, M
1-antitrypsin 24 h + P14-P3 antithrombin 12-mer
peptide; lane 7, NS(S49P); lane 8 is NS(S49P)
24 h; lane 9, NS(S49P) 24 h + P7-P2
1-antitrypsin 6-mer peptide; lane 10 is
NS(S49P) 24 h + P14-P3 antithrombin 12-mer peptide; lane
11, NS; lane 12, NS 24 h; lane 13, NS
24 h + P7-P2 1-antitrypsin 6-mer peptide;
lane 14, NS 24 h + P14-P3 antithrombin 12-mer peptide.
The lower band seen with NS is probably because of a small
amount of the latent conformation.
|
|
 |
DISCUSSION |
The familial dementia, FENIB, is characterized by intraneuronal
inclusions of mutant S49P neuroserpin (8). The principal aim of this
study was to assess the biochemical differences between NS and
NS(S49P), in particular their ability to inhibit tPA, their overall
conformation, and the rate at which they formed polymers. Previous work
has shown that NS was capable of forming an SDS-stable complex with
tPA, but the results also indicated that a proportion of the inhibitor
was cleaved (18). It was suggested that this was because of the
turnover of NS by tPA in a substrate reaction as has been described for
other serpins (16, 18). However, there is evidence that cleaved NS
could result from dissociation of the complex. Osterwalder and
colleagues (13, 19) have shown the dissociation of the complex between
tPA and chicken neuroserpin, which has >80% homology to human
neuroserpin and an identical reactive center loop. Our investigations
show conclusively that the generation of the reactive center
loop-cleaved species of NS was mainly because of the dissociation of
the NS·tPA complex.
The progress-curve experiments also demonstrated a dissociation process
and allowed us to calculate a kd of 7 × 105 s
1, close to the one determined directly
from the disappearance of the complex on the gel. This value is similar
to the value determined for chicken neuroserpin and seems to indicate a
general mechanism for the inhibition of neuroserpin in different
species. The rate of association ka determined
by our experiments (1.2 × 104
M
1 s
1) was lower than the one
determined previously (8 × 104
M
1 s
1) (18). This result may
be partly attributed to the use of a recombinant protein produced in
E. coli as was previously found for
1-antitrypsin where the ka was
reduced 2-3-fold compared with the one obtained with
1-antitrypsin purified from plasma (41). An alternative
possibility is that the previous results did not take into account the
dissociation effect, thereby overestimating ka.
Nevertheless, NS remains a very good inhibitor of tPA in
vitro with an equilibrium dissociation constant
Ki in the nanomolar range (5.8 nM). It
is not clear whether the dissociation process plays a major role
in vivo, in particular in the regulation of tPA activity,
because the exact amount of NS in the brain is unknown. This is an
important factor, because the yield of NS will determine the in
vivo inhibition frequency, and at high concentration, the inhibition by NS could follow a two-step mechanism, leading to an
overall faster inhibition of tPA (42).
In contrast with NS, NS(S49P) showed a decrease in
ka and a dramatic increase in
kd with an overall increase in
Ki of almost 100-fold. This high
Ki prevented the determination of an exact
stoichiometry of inhibition, because even at a concentration of
NS(S49P) of 5 µM, the dissociation competed with the
association process (t1/2 ~7 min for the
dissociation and t1/2 ~1 min for the association at equimolar concentration). However, the small amount of
NS(S49P)·tPA complex that did form as seen on SDS-PAGE (Fig.
2C), even after a relative short period of time, combined
with a measurable ka by our kinetic experiments
indicates that both a substrate pathway and dissociation of the complex
are possible. These results clearly indicate a loss of function
associated with NS(S49P) and suggest that some of the symptoms of FENIB
may be because of a lack of proteinase inhibitor (8).
Our results also provide strong support for the role of polymerization
in the formation of the inclusions that are characteristic of FENIB
(8). The NS(S49P) mutation that underlies FENIB is in the shutter
domain of the protein. This region controls access of the reactive
center loop to
-sheet A and if perturbed will favor polymer
formation (8, 48). Whereas this finding was proven by the
examination of ex vivo inclusions, the polymerization of
wild-type and mutant NS has never been assessed using purified protein.
The polymerization rate of recombinant NS(S49P) at 37 °C was 13-fold
faster than NS when assessed spectroscopically (Table II).
Polymerization was also apparent at lower temperatures for NS(S49P)
with the formation of polymers being seen at temperatures as low as
4 °C (Fig. 5B).
The differences between NS and NS(S49P) were assessed by measuring
melting temperature and assessing the overall conformation of the
protein using CD. A comparison of the melting curve for NS and NS(S49P)
showed a melting point 5 °C lower for NS(S49P) (Fig. 3, A
and B). An analysis of the CD spectra showed that polymers of NS and monomeric NS(S49P) have a very similar overall configuration, but that monomeric NS and NS(S49P) show striking differences. This does
not result from the NS(S49P) being present in the cleaved form or as
denatured protein, because it had an unfolding profile on transverse
urea gradient PAGE that is characteristic of a native serpin (Fig.
3C). It is likely that the reactive center loop and
-sheet A in NS(S49P) are in a conformation that is intermediate between that of wild-type protein and fully formed polymers. Such a
conformation was predicted for Z
1-antitrypsin (and
called M*) and later confirmed by our crystal structure of a shutter domain mutant of another serpin
1-antichymotrypsin (48,
49). In this conformer
-sheet A was widely patent and the reactive loop partly inserted. Thus, it is likely that the configuration of the
mutant NS(S49P) is similar to that described for M*
1-antitrypsin and that this explains the differences
seen on CD analysis and the ready formation of polymers in
vitro and in vivo.
The polymerization of
1-antitrypsin and other serpins
can be blocked by 11-13-mer peptides that correspond to residues
P14-P3 of the reactive center loop of antithrombin (30, 50-53). More recently, we have also demonstrated that the conformation of M* in Z
1-antitrypsin can be specifically targeted using a 6-mer peptide corresponding to residues P7-P2 of the reactive loop that anneals to the lower part of
-sheet A (46). Neither of these peptides was able to anneal to NS or NS(S49P) and prevent polymer formation. This demonstrates that NS has more stringent requirements than other serpins for accepting exogenous reactive center loop peptides.
Taken together, our results strongly support the role of polymerization
in the aggregation of mutant neuroserpin in the brain of individuals
with FENIB. They also show that any NS(S49P) that does not polymerize
will be a poor inhibitor of the target proteinase tPA, which may be
important in the pathophysiology of FENIB.
 |
FOOTNOTES |
*
This work was supported by the Medical Research Council
(United Kingdom) and the Wellcome Trust (United Kingdom).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 44-1223-336825;
Fax: 44-1223-336827; E-mail: db301@cam.ac.uk.
Recipient of Wellcome Trust Advanced Clinical Fellowship.
Published, JBC Papers in Press, March 5, 2002, DOI 10.1074/jbc.M200680200
2
By convention, serpin-reactive center loop
residues are numbered according to the nomenclature of Schechter and
Berger (54) for substrates and proteases. The scissile bond in the
serpin is denoted as P1-P1'. Residues that are N terminus to P1 are P2, P3, and so forth, and residues C terminus to P1' are P2', P3', and so forth.
 |
ABBREVIATIONS |
The abbreviations used are:
FENIB, familial encephalopathy with neuroserpin inclusion bodies;
tPA, tissue
plasminogen activator;
NS, wild-type neuroserpin;
NS(S49P), mutant
neuroserpin S49P.
 |
REFERENCES |
| 1.
|
Lansbury, P. T., Jr.
(1997)
Neuron
19,
1151-1154[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kakizuka, A.
(1998)
Trends Genet.
14,
396-402[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Tran, P. B.,
and Miller, R. J.
(1999)
Trends Neurosci.
22,
194-197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Carrell, R. W.,
and Lomas, D. A.
(1997)
Lancet
350,
134-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Carrell, R. W.,
and Gooptu, B.
(1998)
Curr. Opin. Struct. Biol.
8,
799-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Carrell, R. W.,
and Lomas, D. A.
(2002)
N. Engl. J. Med.
346,
45-53[Free Full Text]
|
| 7.
|
Davis, R. L.,
Holohan, P. D.,
Shrimpton, A. E.,
Tatum, A. H.,
Daucher, J.,
Collins, G. H.,
Todd, R.,
Bradshaw, C.,
Kent, P.,
Feiglin, D.,
Rosenbaum, A.,
Yerby, M. S.,
Shaw, C. M.,
Lacbawan, F.,
and Lawrence, D. A.
(1999)
Am. J. Pathol.
155,
1901-1913[Abstract/Free Full Text]
|
| 8.
|
Davis, R. L.,
Shrimpton, A. E.,
Holohan, P. D.,
Bradshaw, C.,
Feiglin, D.,
Collins, G. H.,
Sonderegger, P.,
Kinter, J.,
Becker, L. M.,
Lacbawan, F.,
Krasnewich, D.,
Muenke, M.,
Lawrence, D. A.,
Yerby, M. S.,
Shaw, C. M.,
Gooptu, B.,
Elliott, P. R.,
Finch, J. T.,
Carrell, R. W.,
and Lomas, D. A.
(1999)
Nature
401,
376-379[Medline]
[Order article via Infotrieve]
|
| 9.
|
Takao, M.,
Benson, M. D.,
Murrell, J. R.,
Yazaki, M.,
Piccardo, P.,
Unverzagt, F. W.,
Davis, R. L.,
Holohan, P. D.,
Lawrence, D. A.,
Richardson, R.,
Farlow, M. R.,
and Ghetti, B.
(2000)
J. Neuropathol. Exp. Neurol.
59,
1070-1086[Medline]
[Order article via Infotrieve]
|
| 10.
|
Bradshaw, C. B.,
Davis, R. L.,
Shrimpton, A. E.,
Holohan, P. D.,
Rea, C. B.,
Fieglin, D.,
Kent, P.,
and Collins, G. H.
(2001)
Arch. Neurol.
58,
1429-1434[Abstract/Free Full Text]
|
| 11.
|
Stoeckli, E. T.,
Lemkin, P. F.,
Kuhn, T. B.,
Ruegg, M. A.,
Heller, M.,
and Sonderegger, P.
(1989)
Eur. J. Biochem.
180,
249-258[Medline]
[Order article via Infotrieve]
|
| 12.
|
Osterwalder, T.,
Contartese, J.,
Stoeckli, E. T.,
Kuhn, T. B.,
and Sonderegger, P.
(1996)
EMBO J.
15,
2944-2953[Medline]
[Order article via Infotrieve]
|
| 13.
|
Krueger, S. R.,
Ghisu, G. P.,
Cinelli, P.,
Gschwend, T. P.,
Osterwalder, T.,
Wolfer, D. P.,
and Sonderegger, P.
(1997)
J. Neurosci.
17,
8984-8996[Abstract/Free Full Text]
|
| 14.
|
Schrimpf, S. P.,
Bleiker, A. J.,
Brecevic, L.,
Kozlov, S. V.,
Berger, P.,
Osterwalder, T.,
Krueger, S. R.,
Schinzel, A.,
and Sonderegger, P.
(1997)
Genomics
40,
55-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Hill, R. M.,
Parmar, P. K.,
Coates, L. C.,
Mezey, E.,
Pearson, J. F.,
and Birch, N. P.
(2000)
Biochem. J.
345,
595-601[Medline]
[Order article via Infotrieve]
|
| 16.
|
Silverman, G. A.,
Bird, P. I.,
Carrell, R. W.,
Coughlin, P. B.,
Gettins, P. G.,
Irving, J. I.,
Lomas, D. A.,
Luke, C. J.,
Moyer, R. W.,
Pemberton, P. A.,
Remold-O'Donnell, E.,
Salvesen, G. S.,
Travis, J.,
and Whisstock, J. C.
(2001)
J. Biol. Chem.
276,
33293-33296[Free Full Text]
|
| 17.
|
Huntington, J. A.,
Read, R. J.,
and Carrell, R. W.
(2000)
Nature
407,
923-926[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Hastings, G. A.,
Coleman, T. A.,
Haudenschild, C. C.,
Stefansson, S.,
Smith, E. P.,
Barthlow, R.,
Cherry, S.,
Sandkvist, M.,
and Lawrence, D. A.
(1997)
J. Biol. Chem.
272,
33062-33067[Abstract/Free Full Text]
|
| 19.
|
Osterwalder, T.,
Cinelli, P.,
Baici, A.,
Pennella, A.,
Krueger, S. R.,
Schrimpf, S. P.,
Meins, M.,
and Sonderegger, P.
(1998)
J. Biol. Chem.
273,
2312-2321[Abstract/Free Full Text]
|
| 20.
|
Qian, Z.,
Gilbert, M. E.,
Colicos, M. A.,
Kandel, E. R.,
and Kuhl, D.
(1993)
Nature
361,
453-457[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Huang, Y. Y.,
Bach, M. E.,
Lipp, H. P.,
Zhuo, M.,
Wolfer, D. P.,
Hawkins, R. D.,
Schoonjans, L.,
Kandel, E. R.,
Godfraind, J. M.,
Mulligan, R.,
Collen, D.,
and Carmeliet, P.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8699-8704[Abstract/Free Full Text]
|
| 22.
|
Frey, U.,
Muller, M.,
and Kuhl, D.
(1996)
J. Neurosci.
16,
2057-2063[Abstract/Free Full Text]
|
| 23.
|
Seeds, N. W.,
Williams, B. L.,
and Bickford, P. C.
(1995)
Science
270,
1992-1994[Abstract/Free Full Text]
|
| 24.
|
Tsirka, S. E.,
Rogove, A. D.,
Bugge, T. H.,
Degen, J. L.,
and Strickland, S.
(1997)
J. Neurosci.
17,
543-552[Abstract/Free Full Text]
|
| 25.
|
Wang, Y. F.,
Tsirka, S. E.,
Strickland, S.,
Stieg, P. E.,
Soriano, S. G.,
and Lipton, S. A.
(1998)
Nat. Med.
4,
228-231[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Baranes, D.,
Lederfein, D.,
Huang, Y. Y.,
Chen, M.,
Bailey, C. H.,
and Kandel, E. R.
(1998)
Neuron
21,
813-825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Berger, P.,
Kozlov, S. V.,
Cinelli, P.,
Kruger, S. R.,
Vogt, L.,
and Sonderegger, P.
(1999)
Mol. Cell. Neurosci.
14,
455-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Elliott, P. R.,
Stein, P. E.,
Bilton, D.,
Carrell, R. W.,
and Lomas, D. A.
(1996)
Nat. Struct. Biol.
3,
910-911[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Sivasothy, P.,
Dafforn, T. R.,
Gettins, P. G.,
and Lomas, D. A.
(2000)
J. Biol. Chem.
275,
33663-33668[Abstract/Free Full Text]
|
| 30.
|
Lomas, D. A.,
Evans, D. L.,
Finch, J. T.,
and Carrell, R. W.
(1992)
Nature
357,
605-607[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Lomas, D. A.,
Finch, J. T.,
Seyama, K.,
Nukiwa, T.,
and Carrell, R. W.
(1993)
J. Biol. Chem.
268,
15333-15335[Abstract/Free Full Text]
|
| 32.
|
Lomas, D. A.,
Elliott, P. R.,
Sidhar, S. K.,
Foreman, R. C.,
Finch, J. T.,
Cox, D. W.,
Whisstock, J. C.,
and Carrell, R. W.
(1995)
J. Biol. Chem.
270,
16864-16870[Abstract/Free Full Text]
|
| 33.
|
Eriksson, S.,
Carlson, J.,
and Velez, R.
(1986)
N. Engl. J. Med.
314,
736-739[Abstract]
|
| 34.
|
Briand, C.,
Kozlov, S. V.,
Sonderegger, P.,
and Grutter, M. G.
(2001)
FEBS Lett.
505,
18-22[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Yazaki, M.,
Liepnieks, J. J.,
Murrell, J. R.,
Takao, M.,
Guenther, B.,
Piccardo, P.,
Farlow, M. R.,
Ghetti, B.,
and Benson, M. D.
(2001)
Am. J. Pathol.
158,
227-233[Abstract/Free Full Text]
|
| 36.
|
Yepes, M.,
Sandkvist, M.,
Wong, M. K.,
Coleman, T. A.,
Smith, E.,
Cohan, S. L.,
and Lawrence, D. A.
(2000)
Blood
96,
569-576[Abstract/Free Full Text]
|
| 37.
|
Chen, Z.-L.,
and Strickland, S.
(1997)
Cell
91,
917-925[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Zhou, A.,
Carrell, R. W.,
and Huntington, J. A.
(2001)
J. Biol. Chem.
276,
27541-27547[Abstract/Free Full Text]
|
| 39.
|
Zhou, A.,
Faint, R.,
Charlton, P.,
Dafforn, T. R.,
Carrell, R. W.,
and Lomas, D. A.
(2001)
J. Biol. Chem.
276,
9115-9122[Abstract/Free Full Text]
|
| 40.
|
Renatus, M.,
Engh, R. A.,
Stubbs, M. T.,
Huber, R.,
Fischer, S.,
Kohnert, U.,
and Bode, W.
(1997)
EMBO J.
16,
4797-4805[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Belorgey, D.,
and Bieth, J. G.
(1998)
Biochemistry
37,
16416-16422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Bieth, J. G.
(1995)
Method Enzymol.
248,
59-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Morrison, J. F.,
and Walsh, C. T.
(1988)
Adv. Enzymol. Relat. Areas Mol. Biol.
61,
201-301[Medline]
[Order article via Infotrieve]
|
| 44.
|
Lawrence, D. A.,
Olson, S. T.,
Palaniappan, S.,
and Ginsburg, D.
(1994)
Biochemistry
33,
3643-3649[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Dafforn, T. R.,
Della, M.,
and Miller, A. D.
(2001)
J. Biol. Chem.
276,
49310-49319[Abstract/Free Full Text]
|
| 46.
|
Mahadeva, R.,
Dafforn, T. R.,
Carrell, R. W.,
and Lomas, D. A.
(2002)
J. Biol. Chem.
277,
6771-6774[Abstract/Free Full Text]
|
| 47.
|
Faller, B.,
Cadène, M.,
and Bieth, J. G.
(1993)
Biochemistry
32,
9230-9235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Dafforn, T. R.,
Mahadeva, R.,
Elliott, P. R.,
Sivasothy, P.,
and Lomas, D. A.
(1999)
J. Biol. Chem.
274,
9548-9555[Abstract/Free Full Text]
|
| 49.
|
Gooptu, B.,
Hazes, B.,
Chang, W. S.,
Dafforn, T. R.,
Carrell, R. W.,
Read, R. J.,
and Lomas, D. A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
67-72[Abstract/Free Full Text]
|
| 50.
|
Schulze, A. J.,
Baumann, U.,
Knof, S.,
Jaeger, E.,
Huber, R.,
and Laurell, C. B.
(1990)
Eur. J. Biochem.
194,
51-56[Medline]
[Order article via Infotrieve]
|
| 51.
|
Bjork, I.,
Ylinenjarvi, K.,
Olson, S. T.,
and Bock, P. E.
(1992)
J. Biol. Chem.
267,
1976-1982[Abstract/Free Full Text]
|
| 52.
|
Fitton, H. L.,
Pike, R. N.,
Carrell, R. W.,
and Chang, W. S.
(1997)
Biol. Chem.
378,
1059-1063[Medline]
[Order article via Infotrieve]
|
| 53.
|
Skinner, R.,
Chang, W. S.,
Jin, L.,
Pei, X.,
Huntington, J. A.,
Abrahams, J. P.,
Carrell, R. W.,
and Lomas, D. A.
(1998)
J. Mol. Biol.
283,
9-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Schechter, I.,
and Berger, A.
(1967)
Biochem. Biophys. Res. Commun.
27,
157-162[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Miranda, I. MacLeod, M. J. Davies, J. Perez, K. Romisch, D. C. Crowther, and D. A. Lomas
The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB
Hum. Mol. Genet.,
June 1, 2008;
17(11):
1527 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Nielsen, L. Minthon, E. Londos, K. Blennow, E. Miranda, J. Perez, D. C. Crowther, D. A. Lomas, and S. M. Janciauskiene
Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies
Neurology,
October 16, 2007;
69(16):
1569 - 1579.
[Abstract]
[Full Text]
[PDF]
|
 |
|